Peroxitech Awarded NIH Grant to Develop a Novel Therapeutic Compound for Acute Lung Injury
Philadelphia – June 1, 2020 – Peroxitech Inc., an emerging biopharmaceutical company, has been awarded an NIH grant to continue development of a novel therapeutic compound for the treatment of Acute Lung Injury (ALI).
ALI is a devastating complication of COVID-19, sepsis, viral and bacterial pneumonias, severe trauma and other conditions that affect the lung either primarily or secondarily. ALI has a high mortality rate of approximately 40% and no therapeutic treatments are available. Patients with ALI spend on average 20 days on mechanical ventilation and a total of 30 days in hospital, underscoring the significant resources required to manage this disease and unmet clinical need for a therapeutic intervention.
Peroxitech is developing a novel treatment that has demonstrated protection and rescue from severe ALI in preclinical studies, including a greater than 50% reduction in mortality in severe ALI.
This was achieved by targeting a new pathway that has never been identified for ALI. Studies show this pathway is responsible for a critical ALI oxidative injury cascade.
“We are very excited to continue our development work with our lead compound for the effective treatment of ALI with support from the NIH SEED funding program. Although early, preclinical animal studies show significant efficacy signals for the treatment of ALI” stated Thomas Han, CEO & Co-Founder of Peroxitech.
About Peroxitech
Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury. The company was launched the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures and was seeded at Xontogeny. In addition to the first clinical indication, Peroxitech is also evaluating our lead compound for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.
ALI is a devastating complication of COVID-19, sepsis, viral and bacterial pneumonias, severe trauma and other conditions that affect the lung either primarily or secondarily. ALI has a high mortality rate of approximately 40% and no therapeutic treatments are available. Patients with ALI spend on average 20 days on mechanical ventilation and a total of 30 days in hospital, underscoring the significant resources required to manage this disease and unmet clinical need for a therapeutic intervention.
Peroxitech is developing a novel treatment that has demonstrated protection and rescue from severe ALI in preclinical studies, including a greater than 50% reduction in mortality in severe ALI.
This was achieved by targeting a new pathway that has never been identified for ALI. Studies show this pathway is responsible for a critical ALI oxidative injury cascade.
“We are very excited to continue our development work with our lead compound for the effective treatment of ALI with support from the NIH SEED funding program. Although early, preclinical animal studies show significant efficacy signals for the treatment of ALI” stated Thomas Han, CEO & Co-Founder of Peroxitech.
About Peroxitech
Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury. The company was launched the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures and was seeded at Xontogeny. In addition to the first clinical indication, Peroxitech is also evaluating our lead compound for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.
